An open-label, multi-center, randomized, dose-escalation, phase IB study to evaluate safety, pharmacokinetics and therapeutic activity of ro6874281 in combination with atezolizumab ±bevacizumab in patients with unresectable advanced and/or metastatic renal cell carcinoma